Surgical robotics leader Stereotaxis has announced a definitive agreement to acquire French innovator Robocath in a deal valued at up to $45 million. The acquisition combines Stereotaxis' magnetic navigation with Robocath's mechanical systems to create a comprehensive platform for endovascular procedures. This strategic move aims to solidify Stereotaxis' leadership in interventional cardiology, neurointerventions, and electrophysiology.
A Strategic Combination of Technologies
The merger unites two distinct yet complementary robotic technologies for endovascular surgery. Stereotaxis utilizes precise magnetic fields for navigating interventional devices, while Robocath's platform offers mechanical control of multiple instruments at the bedside. Together, they form a synergistic solution designed to significantly improve procedural precision, safety, and overall efficiency.
Robocath brings its advanced R-One+ system, the only commercially available robotic solution for coronary interventions in Europe. The company has already installed fifteen systems globally and is developing a next-generation platform capable of manipulating five devices simultaneously. This established technology and robust intellectual property portfolio represent a significant asset for Stereotaxis.
Accelerating Innovation and Market Expansion
Stereotaxis plans to fast-track the development of Robocath’s next-generation system, targeting regulatory submissions in the U.S. and Europe within two years. The company will also integrate its proprietary software, including GenesisX and Synchrony, to enable advanced features like automation and remote procedures. This integration will create a seamless, fully-robotic solution for a wider range of interventions.
David Fischel, Stereotaxis Chairman and CEO, described the acquisition as a highly strategic addition that accelerates the company's vision. He emphasized that combining their complementary mechanisms creates a uniquely capable platform, expanding their reach across interventional medicine. Fischel noted the deal enhances their technological leadership and opens new avenues for growth.
From Robocath's perspective, Founder and CEO Philippe Bencteux highlighted the benefits of the merger. He stated that joining Stereotaxis provides the necessary scale and technological alignment to accelerate their development and expand their impact. Bencteux expressed confidence that the combination will unlock significant opportunities in rapidly growing markets.
Financial Implications and Future Outlook
The transaction involves an upfront payment of $20 million, with up to an additional $25 million in contingent payments. These future payments are tied to specific regulatory and commercial milestones, including FDA clearance for Robocath's new system. The acquisition, payable in cash or stock, is expected to close in mid-2026 pending customary conditions.
Following the acquisition, Stereotaxis projects that Robocath will contribute approximately $2 million in annual revenue during the first year. The company anticipates the deal will become breakeven by the third year, driven by commercial and operational synergies. This transaction accelerates Stereotaxis’ entry into vast interventional markets valued at tens of billions annually.
This acquisition marks a pivotal moment for the field of endovascular robotics, creating a formidable industry leader. By integrating magnetic and mechanical technologies, Stereotaxis is poised to offer a comprehensive platform that enhances procedural outcomes and expands access to care. The combined entity is now well-positioned to drive the next wave of innovation in minimally invasive surgery.